Navigation Links
Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited
Date:7/5/2009

red around a class of small peptide molecules called lantibiotics, a drug class that, until now, has been underexploited due to the lack of adequate research tools. Novacta's lantibiotic platform has given rise to a number of potential drug candidates, including those in the C. difficile programme. Other programmes include one targeting methicillin-resistant Staphylococcus aureus (MRSA) infection and others targeting Gram-negative infections. For further information, please visit our website at www.novactabio.com.

About Lantibiotics

Lantibiotics are a naturally occurring class of antibiotic peptide compounds found in a large number of bacteria. They take their name from the lanthionine amino acids found within their structure ( lanthionine-containing antibiotics). Lantibiotics have demonstrated potential to treat infections caused by agents such as C. difficile and MRSA. Conventional medicinal chemistry has been unable to manipulate the structure of the naturally occurring compounds into the optimised forms that have the potential to treat human disease. However, Novacta's proprietary technologies allow the structural manipulation and optimisation of activity which is necessary to unlock the potential of this novel and under-exploited class of compounds.

    Please contact with enquiries:

    Celtic Pharma Holdings Advisors
    John Mayo / Stephen Parker
    LLP
    Tel: +44(20)7291-5456
    stephen.parker@celticpharmaholdings.com

    Novacta Biosystems Ltd.
    Georg Buchner
    VP, Corporate & Business Development
    Tel: +44(0)1707-356130
    georg.buchner@novactabio.com

    Citigate Dewe Rogerson Limited
    David Dible / Chris Gardner
    Tel: +44(0)20-7638-9571
    david.dible@
'/>"/>

SOURCE Celtic Pharma Holdings Advisors LLP
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
2. iCardiac Selected by Top 10 Pharmaceutical Company
3. WuXi PharmaTech Receives Award from BASF
4. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
5. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
6. Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization
7. Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
8. OncoGenex Pharmaceuticals Added to Russell Indexes
9. Asia Debut for Money-Saving Pharma-Packaging Machines from Ireland
10. Pharmaxis Closes Share Purchase Plan
11. ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... (PRWEB) April 28, 2015 The ... a Massachusetts-based multi-stakeholder, non-profit organization dedicated to transforming ... a shared global system for clinical research, announced ... an innovative new type of clinical research event ... of clinical research is changing,” said Greg Koski, ...
(Date:4/27/2015)... , Alemania, April 27, 2015 ... nuevo receptor utilizando tecnología de descubrimiento de biomarcador computacional  ... el tratamiento de millones de pacientes con cáncer   ... ha recibido una patente en Europa titulada "Tissue Protective ... Molecular Health de que EPHB4 es un nuevo receptor ...
(Date:4/27/2015)... Deadly viruses such as Ebola are ... the University City Science Center's Port business ... With a $4.5 million Phase 2 SBIR grant from ... Therapeutics is focused on therapies for unmet medical ... is developing first-in-class protease inhibitors based on a technology ...
(Date:4/27/2015)... , April 27, 2015   Aratana ... pet therapeutics company focused on the licensing, development ... animals, today provided commentary on clinical study data ... a poster session at the American Association for ... ADXS31-164 is a novel Lm -LLO immunotherapy ...
Breaking Biology Technology:ACRES Announces Innovative Clinical Research Event--SYNERGY 2ACRES Announces Innovative Clinical Research Event--SYNERGY 3ACRES Announces Innovative Clinical Research Event--SYNERGY 4Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola 2Aratana Therapeutics Comments on ADXS31-164 (AT-014) Study Data Presented During Poster Session at the American Association for Cancer Research (AACR) Annual Meeting 2015 2
... COLUMBIA, Md., Sept. 2 ACell, Inc. is announcing ... , , The conference will be held ... Palace Hotel in New York City. James DeFrancesco, Chief Executive Officer ... 11th beginning at 9:10 AM (EDT) in the Hubbard Room. The ...
... HAYWARD, Calif., Sept. 2 Advanced Cell Diagnostics, Inc. ... of its Series A equity financing from Morningside Ventures, bringing ... , , ACD will use the funds ... on the company,s patent pending RNAscope(TM) technology. "This second closing ...
... , , INDIANAPOLIS, Sept. 2 ... announced that, effective October 1, 2009, it would increase the ... kg for all non-contract customers or as existing contracts permit. ... invest in expanding global supply for the high performance, reducing ...
Cached Biology Technology:ACell's CEO to Present at Rodman & Renshaw's 2009 Annual Global Investment Conference 2ACD Completes the Second Closing of Series A Financing and Initiates Services for Biomarker Validation and Companion Diagnostic Development 2
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/17/2015)... , April 17, 2015 ... concerns, and technological advancement to drive biometric systems ... until 2020   According to a ... Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... to register growth at CAGR of over 22% ...
(Date:4/14/2015)... 14, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... 2015 New York Design Awards under the category  ,Product ... City Design Awards are part of a global multi-disciplinary ... ratings from the marketplace, industry and judging panel. Winners ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... 6, 2013) -- Researchers at Weill Cornell Medical College have ... circuits in a developing brain -- gaining unprecedented insight into ... from autism to mental retardation. In the journal ... faulty wiring occurs when RNA molecules embedded in a growing ...
... of treatment for patients with end-stage liver disease, the 12th ... research from the Icahn School of Medicine at Mount Sinai, ... today, suggests that it may one day become possible to ... disease. Investigators discovered that a human embryonic stem cell can ...
... of vitamin D are associated with high levels of hepatitis ... , a journal of the American Association for the Study ... HBV levels point to a link in these variables among ... are available, HBV still remains one of the most significant ...
Cached Biology News:Researchers discover how brain circuits can become miswired during development 2Researchers discover how brain circuits can become miswired during development 3Mount Sinai discovers new liver cell for cellular therapy to aid in liver regeneration 2Vitamin D deficiency may help spread of hepatitis B throughout liver 2
... mir Vana miRNA Bioarray Essentials Kit provides ... and post-hybridization washing of the mir Vana ... has been labeled using Ambions mir Vana ... positive control miRNA (Bioarray ID BA10001) that should ...
... Intracellular Localization Kit provides a straight forward ... of your design, in an efficient yet ... Subcellular localization and functional inhibition of target ... of the labeled siRNA into mammalian cells. ...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: box ...
... The InnoCyte Laminin-Based 96-well Cell Invasion Assay ... of cells using laminin as a significant ... anti-metastatic agents in vitro in a convenient, ... size is appropriate for all types of ...
Biology Products: